This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow P3Rs: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when P3Rs are posted
Right arrow Alert me if a correction is posted
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My File Cabinet
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Bouthillier;, M. J
Right arrow Articles by Top, F. H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bouthillier;, M. J
Right arrow Articles by Top, F. H., Jr

PEDIATRICS Vol. 100 No. 2 August 1997, pp. 275-276

RespiGam/PREVENT Study Questioned

The first 20% of the full text of this article appears below.

To the Editor.

The publication of the PREVENT trial allows the first opportunity to critically analyze data used by the Food and Drug Administration over 1 year ago to approve RespiGam for reducing the incidence and duration of respiratory syncytial virus (RSV) hospitalization.1 The PREVENT Study Group concluded that RespiGam prophylaxis . . . [Full Text of this Article]